Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models, with the results supporting further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
Osteosarcoma is a type of bone cancer that affects both humans and dogs, and the similarity of the disease in canines to human osteosarcoma makes it a valuable model for drug development. The fact that Telomir-Zn inhibited growth in both human and canine cell lines at similar low concentrations suggests a potential cross-species efficacy that could accelerate research and development.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma, which could support both veterinary development and translational advancement toward human osteosarcoma. The company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared IND for advanced or metastatic TNBC.
This news matters because it highlights a potential new therapeutic approach for osteosarcoma, a cancer with limited treatment options, especially for patients with metastatic disease. If further studies confirm these findings, Telomir-Zn could offer a new avenue for treating both canine and human osteosarcoma, addressing a significant unmet medical need. The use of naturally occurring canine osteosarcoma as a translational model could also speed up the development process, benefiting both veterinary and human patients.
For investors, the announcement signals progress in Telomir’s pipeline beyond its lead breast cancer program, potentially expanding the company’s market opportunities. The successful development of Telomir-Zn for osteosarcoma could open up a new revenue stream and strengthen Telomir’s position in the oncology space. However, the company’s immediate focus remains on its triple-negative breast cancer program, which is advancing toward clinical trials.
To view the full press release, visit https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO.
